Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Bayer

< Previous 1 2 3 4 5 6 7 8 9 Next >
Bayer Highlights New Data from Oncology and Women’s Health Portfolios at 2025 ASCO Annual Meeting
From Bayer
Via Business Wire
U.S. FDA Grants Approval for Jivi® Antihemophilic Factor (Recombinant), PEGylated-aucl in Pediatric Patients 7 to Under 12 Years of Age With Hemophilia A (Congenital Factor VIII Deficiency)
From Bayer
Via Business Wire
Passage of New Georgia Bill a Win for Farmers
From Bayer
Via Business Wire
Bayer U.S. Surveys Shed Further Light on the Diversity of Menopause Care Approaches and Menopause Symptom Experiences
From Bayer
Via Business Wire
Don’t Let Corn Rootworm Steal Your Yield: Bayer Launches The Watch 2025
From Bayer
Via Business Wire
AUA 2025: New Data from Post-Hoc Analyses Shared on Ultra-Low Prostate-Specific Antigen (PSA) Response in Patients with Metastatic Hormone-Sensitive Prostate Cancer Receiving NUBEQA® (darolutamide) plus Androgen Deprivation Therapy (ADT)
From Bayer
Via Business Wire
Bayer Initiates Phase I Study Targeting GPC3 With Actinium-225 Radiopharmaceutical in Patients With Advanced Hepatocellular Carcinoma
From Bayer
Via Business Wire
Guru Ramamurthy Appointed as New CFO for Bayer’s Crop Science Division
From Bayer
Via Business Wire
Agricultural Community Applauds Signing of New North Dakota Bill
From Bayer
Via Business Wire
Bayer Unveils $44 Million Investment in Myerstown, PA Manufacturing Facility, Renewing Commitment to U.S. Innovation, Health and Community
From Bayer
Via Business Wire
Bayer to Unveil Latest NUBEQA® (darolutamide) Data and Prostate Cancer Research at American Urological Association (AUA) 2025 Annual Meeting
From Bayer
Via Business Wire
U.S. FDA Grants Full Approval of VITRAKVI® (larotrectinib) for Adult and Pediatric Patients with NTRK Gene Fusion-Positive Solid Tumors
From Bayer
Via Business Wire
Bayer announces filing of petition to U.S. Supreme Court for review of Durnell Roundup™ case
From Bayer
Via Business Wire
Comprehensive Review of More Than 400 Studies Conducted Over 30 Years:
From Bayer
Via Business Wire
ACC.25: Bayer Presents New Investigational Heart Failure Data and Continued Portfolio Research in Chronic Kidney Disease in Type 2 Diabetes
From Bayer
Via Business Wire
Dr. Mike Graham Appointed as New Head of R&D for Bayer’s Crop Science Division
From Bayer
Via Business Wire
U.S. FDA Accepts Supplemental New Drug Application Under Priority Review for New Indication for KERENDIA® (finerenone) in Patients with Heart Failure with Left Ventricular Ejection Fraction of ≥40%
From Bayer
Via Business Wire
Bayer Introduces Vyconic™ Soybeans, a Groundbreaking Advance in Weed Management, at Commodity Classic 2025
From Bayer
Via Business Wire
Late-breaking data from QUANTI CNS (Central Nervous System) presented at ECR 2025:
From Bayer
Via Business Wire
Bayer® Aspirin Continues Longstanding Commitment to Heart Health Education, Encouraging Americans to “See Their Risks”
From Bayer
Via Business Wire
New Data for NUBEQA® Build on Safety and Efficacy Results Across Subgroups of Patients with Metastatic Hormone-Sensitive Prostate Cancer
From Bayer
Via Business Wire
Bayer Unveils Latest Data from Prostate Cancer Portfolio at 2025 ASCO GU Cancers Symposium
From Bayer
Via Business Wire
Leaps by Bayer Announces One of the Largest Global Surveys of Society’s Attitudes Toward Breakthrough Technologies
From Bayer
Via Business Wire
New U.S. Survey Conducted On Behalf Of One A Day® by Bayer Highlights Four in Five GenZ Women Feel Societal Pressures Impact Their New Year’s Resolutions
From Bayer
Via Business Wire
Bayer’s Pharma Growth Strategy Progressing Well as Pipeline Advances
From Bayer
Via Business Wire
Bayer’s investigational MRI contrast agent gadoquatrane meets primary and main secondary endpoints in pivotal Phase III studies
From Bayer
Via Business Wire
Bayer Submits Supplemental New Drug Application to U.S. FDA Seeking New Indication for KERENDIA® (finerenone) in Patients with Heart Failure with Left Ventricular Ejection Fraction of ≥40%
From Bayer
Via Business Wire
Elinzanetant Meets All Primary and Secondary Endpoints in Phase III Study OASIS 4 for Treatment of Moderate to Severe Vasomotor Symptoms Caused by Breast Cancer Treatments
From Bayer
Via Business Wire
Bayer: Federal Court Brings an End to Roundup™ Litigation in Australia
From Bayer
Via Business Wire
Bayer Partners with America’s Grow-A-Row to Aid in the Fight Against Hunger in New Jersey
From Bayer
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.